Latest Breaking News On - Investment in biotechnology companies - Page 6 : vimarsana.com

Opthea To Present at H.C. Wainwright BIOCONNECT Virtual Conference

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST ...

MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced

Opthea Opens Patient Enrollment in the Asia-Pacific Region

MELBOURNE, Australia, Oct. 19, 2021 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel.

Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD

Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD - read this article along with other careers information, tips and advice on BioSpace

Opthea Appoints Julia A. Haller, MD, and Judith Robertson

Opthea Appoints Company Secretary and Vice President of Finance

Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors

Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors - read this article along with other careers information, tips and advice on BioSpace

Opthea Company Secretary Resignation

MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Company, with effect 24 June 2021. Opthea has initiated a search for a permanent replacement with requisite expertise in financial reporting and company secretarial duties for a dual ASX and Nasdaq listed company. Mr Tonroe leaves Opthea at a time of corporate growth and emerging presence in the US to align with the recent listing on Nasdaq and initiation of the Company’s global Phase 3 clinical development program for OPT-302 in wet age-related macular degeneration (wet AMD).

Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference

MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a.